These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

633 related articles for article (PubMed ID: 11187862)

  • 1. Hemophilia factor VIII therapy. Immunological tolerance. A clinical perspective.
    White GC; Greenwood R; Escobar M; Frelinger JA
    Haematologica; 2000 Oct; 85(10 Suppl):113-6. PubMed ID: 11187862
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hemophilia. Strategies for the treatment of inhibitor patients.
    Ingerslev J
    Haematologica; 2000 Oct; 85(10 Suppl):15-20. PubMed ID: 11187863
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibitors of factor VIII: detection and treatment.
    Brettler DB
    Southeast Asian J Trop Med Public Health; 1993; 24 Suppl 1():21-5. PubMed ID: 7886576
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibodies to factor VIII in hemophilia A patients.
    Brackmann HH; Schwaab R; Effenberger W; Hess L; Hanfland P; Oldenburg J
    Vox Sang; 2000; 78 Suppl 2():187-90. PubMed ID: 10938950
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune tolerance in hemophilia with factor VIII inhibitors: predictors of success.
    Mariani G; Kroner B;
    Haematologica; 2001 Nov; 86(11):1186-93. PubMed ID: 11694405
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Factor VIII inhibitors: role of von Willebrand factor on the uptake of factor VIII by dendritic cells.
    Kaveri SV; Dasgupta S; Andre S; Navarrete AM; Repessé Y; Wootla B; Lacroix-Desmazes S
    Haemophilia; 2007 Dec; 13 Suppl 5():61-4. PubMed ID: 18078399
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factor VIII inhibitors. Potential for prevention of inhibitor formation by immune tolerance.
    Kaplan J; Genyea C; Secord E
    Semin Thromb Hemost; 2000; 26(2):173-8. PubMed ID: 10919410
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The maintenance of tolerance after successful immune tolerance induction in hemophilia A and B: the North American Registry. Factor VIII/IX Subcommittee of the International Society for Thrombosis and Hemostasis.
    DiMichele D; Kroner B;
    Haematologica; 2000 Oct; 85(10 Suppl):40-2; discussion 42-4. PubMed ID: 11187869
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanisms of action of immune tolerance induction against factor VIII in patients with congenital haemophilia A and factor VIII inhibitors.
    Reipert BM; van Helden PM; Schwarz HP; Hausl C
    Br J Haematol; 2007 Jan; 136(1):12-25. PubMed ID: 17222196
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune tolerance therapy for haemophilia A patients with acquired factor VIII alloantibodies: comprehensive analysis of experience at a single institution.
    Smith MP; Spence KJ; Waters EL; Beresford-Webb R; Mitchell MJ; Cuttler J; Alhaq A; Brown SA; Savidge GF
    Thromb Haemost; 1999 Jan; 81(1):35-8. PubMed ID: 9974371
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunological aspects of inhibitor development.
    Reding MT
    Haemophilia; 2006 Dec; 12 Suppl 6():30-5; discussion 35-6. PubMed ID: 17123391
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Induction of immune tolerance with factor VIII concentrate in patients with hemophilia A and inhibitors.
    Ewing NP
    Prog Clin Biol Res; 1990; 324():59-68. PubMed ID: 2106693
    [No Abstract]   [Full Text] [Related]  

  • 13. Immunogenicity and immune tolerance coagulation Factors VIII and IX.
    Rup B
    Dev Biol (Basel); 2003; 112():55-9. PubMed ID: 12762504
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Application of current knowledge to the management of bleeding events during immune tolerance induction.
    Di Paola J; Aledort L; Britton H; Carcao M; Grabowski E; Hutter J; Journeycake J; Kempton C; Leissinger C
    Haemophilia; 2006 Nov; 12(6):591-7. PubMed ID: 17083508
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Immune tolerance therapy for inhibitors in haemophilia A].
    Oldenburg J
    Hamostaseologie; 2008 Oct; 28 Suppl 1():S23-5. PubMed ID: 18958334
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rituximab in the treatment of alloimmune factor VIII and IX antibodies in two children with severe haemophilia.
    Mathias M; Khair K; Hann I; Liesner R
    Br J Haematol; 2004 May; 125(3):366-8. PubMed ID: 15086418
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibitor antibody development and T cell response to human factor VIII in murine hemophilia A.
    Qian J; Borovok M; Bi L; Kazazian HH; Hoyer LW
    Thromb Haemost; 1999 Feb; 81(2):240-4. PubMed ID: 10063999
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunetolerance as treatment of alloantibodies to factor VIII in hemophilia. The International Registry of Immunetolerance Protocols.
    Mariani G; Scheibel E; Nogao T; Kasper CK; Ewing NP; Mauser-Bunschoten E; Ghirardini A; Bellocco R; Brackman HH
    Semin Hematol; 1994 Apr; 31(2 Suppl 4):62-4. PubMed ID: 7939781
    [No Abstract]   [Full Text] [Related]  

  • 19. The treatment of factor VIII inhibitors--a general overview.
    White GC; Roberts HR
    Vox Sang; 1996; 70 Suppl 1():19-23. PubMed ID: 8869464
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The prevalence of proteolytic antibodies against factor VIII in hemophilia A.
    Lacroix-Desmazes S; Bayry J; Misra N; Horn MP; Villard S; Pashov A; Stieltjes N; d'Oiron R; Saint-Remy JM; Hoebeke J; Kazatchkine MD; Reinbolt J; Mohanty D; Kaveri SV
    N Engl J Med; 2002 Feb; 346(9):662-7. PubMed ID: 11870243
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.